Why CAR-T Cell Therapy Stocks Are Surging in 2026

The CAR-T cell therapy market was worth $8.95 billion in 2025. Fortune Business Insights projects it at $19.25 billion by 2034, a CAGR of 11.9%. That growth is not speculation. Three regulatory decisions in the last 12 months have expanded the addressable patient population, a new drug class called CELMoDs is extending the durability of CAR-T combinations, and manufacturing innovations are cutting the cost per dose from $500,000 toward $200,000. The stocks moving on this theme are not the usual suspects.

Three Expansions That Changed the Math

CAR-T therapies were approved in hematologic cancers first: leukemia, lymphoma, multiple myeloma. The addressable patient population was small, the manufacturing was bespoke, and the price was $375,000 to $475,000 per dose. Three developments have changed the math.

1. Bristol Myers Squibb’s Zenbexus (iberdomide) approval on August 13, 2026. The FDA granted accelerated approval to iberdomide, the first CELMoD (cereblon-modulating protein degrader), in combination with daratumumab and dexamethasone for multiple myeloma patients who have received at least one prior line of therapy. The Phase 3 EXCALIBER-RRMM trial showed 41% MRD-negative complete response versus 21% for the daratumumab-bortezomib-dexamethasone comparator (p<0.0001). This matters for CAR-T because iberdomide is being studied as a bridging therapy and as a combination partner with BCMA-directed CAR-T. A better bridging therapy means more patients are healthy enough to survive the manufacturing wait. A better combination partner means CAR-T may work longer before relapse.

2. Gilead’s anito-cel BCMA CAR-T. Gilead (GILD) is developing anito-cel as a next-generation BCMA-directed CAR-T for multiple myeloma, with a PDUFA date we analyzed in our anito-cel PDUFA breakdown. The drug is designed to address the durability problem that plagued earlier BCMA CAR-Ts: median progression-free survival of 9 to 15 months before relapse. If anito-cel extends PFS past 18 months, it changes the cost-effectiveness calculation for payers and expands the eligible patient pool.

3. Autolus Therapeutics (AUTL) and the pediatric ALL expansion. Autolus received approval for its CD19-directed CAR-T in pediatric acute lymphoblastic leukemia, expanding the addressable population into patients under 25. The pediatric ALL market is small in patient count (roughly 3,000 new cases per year in the US) but the cure rate with CAR-T is high enough that payers are willing to pay $400,000+ per dose. The pediatric approval also validates the manufacturing platform for future indications.

The CELMoD Connection

The iberdomide approval is the catalyst that ties the CAR-T story together. Here is why.

Multiple myeloma is the largest CAR-T market. BCMA-directed CAR-Ts (Abecma from BMS/2seventy, Carvykti from J&J/Legend) are approved in relapsed/refractory myeloma after four prior lines. The problem: patients who reach fourth-line therapy are often too sick to survive the 3-4 week CAR-T manufacturing process. The median age at diagnosis is 69. By fourth line, patients have comorbidities, bone marrow failure, and diminished T-cell fitness. Their T-cells, which are the raw material for CAR-T manufacturing, are exhausted.

CELMoDs solve this in two ways. First, they work earlier in the disease. Iberdomide is approved after one prior line, not four. That means patients get CELMoD therapy while their T-cells are still healthy. If the disease progresses, the CAR-T manufacturing process starts with better T-cells. Second, CELMoDs are being studied as maintenance therapy after CAR-T, potentially extending the duration of response.

The 41% MRD-negative rate in EXCALIBER-RRMM is the deepest response ever seen in a first-relapse myeloma trial. MRD negativity means the cancer is undetectable at the molecular level. Patients who achieve MRD negativity have longer progression-free survival. If iberdomide gets patients to MRD-negative status before CAR-T, the CAR-T starts from a lower disease burden, which correlates with better outcomes.

For our deep dive on the CAR-T vs. bispecific trade-off in myeloma, see CAR-T vs. bispecifics in multiple myeloma. For the broader cell therapy pipeline beyond CAR-T, see cell therapy beyond CAR-T: CAR-NK and TIL.

Manufacturing: The Bottleneck Is Breaking

The cost of CAR-T therapy is not just the drug. It is the manufacturing. The current process involves: leukapheresis (harvesting the patient’s T-cells), shipping to a centralized manufacturing facility, genetically modifying the T-cells with a lentiviral or retroviral vector, expanding them over 7-14 days, cryopreserving, shipping back, and infusing. The total process takes 3-4 weeks. During that time, the patient needs bridging therapy, which adds cost and toxicity.

Three manufacturing innovations are changing this:

1. In vivo CAR-T. Instead of harvesting T-cells and modifying them in a lab, in vivo CAR-T uses a viral vector or lipid nanoparticle to deliver the CAR gene directly into the patient’s T-cells inside their body. This eliminates the leukapheresis, the centralized manufacturing, and the 3-4 week wait. Johnson & Johnson’s acquisition of an in vivo CAR-T platform, covered in our J&J in vivo CAR-T deal analysis, is the biggest bet on this approach.

2. Allogeneic (off-the-shelf) CAR-T. Instead of using the patient’s own T-cells, allogeneic CAR-T uses healthy donor T-cells that are genetically modified to avoid graft-versus-host disease. The advantage: the CAR-T can be manufactured in bulk, cryopreserved, and shipped on demand. The disadvantage: allogeneic CAR-Ts have shorter persistence than autologous, and the persistence problem is the reason the first generation of allogeneic CAR-Ts failed. The second generation is in Phase 2. For the technical comparison, see our autologous vs. allogeneic CAR-T guide.

3. Point-of-care manufacturing. Several academic centers are building on-site CAR-T manufacturing facilities that cut the process from 3-4 weeks to 7-10 days. This requires capital investment but eliminates shipping and reduces the bridging therapy burden.

The Stocks

Three categories of CAR-T stocks are worth tracking:

The incumbents: Bristol Myers Squibb (BMY), Gilead (GILD), Johnson & Johnson (JNJ). These are the companies with approved CAR-T products. They move on label expansions, new combination data, and manufacturing scale. BMY at $120 billion market cap moves 5% to 10% on a CAR-T catalyst. GILD at $80 billion moves similarly. JNJ at $400 billion does not move on CAR-T alone, but the in vivo CAR-T platform is a strategic play that could add $10 billion to $20 billion in enterprise value if it works.

The pure-plays: Autolus Therapeutics (AUTL), Century Therapeutics (IPSC), Allogene Therapeutics (ALLO). These are smaller companies ($200 million to $2 billion market cap) where a single CAR-T approval or Phase 2 readout can move the stock 50% to 100%. The risk is binary: one failed trial can cut the stock in half.

The picks-and-shovels: The viral vector manufacturers (Lonza, Catalent), the cell therapy CROs, and the apheresis networks. These companies do not move on individual CAR-T data but benefit from the overall growth in the cell therapy market. Lower risk, lower reward, but the market is growing at 11.9% CAGR.

For a ranked list of cell therapy stocks to watch in 2026, see our CAR-T stocks investing guide. For the manufacturing bottlenecks that determine which CAR-T programs succeed, see CAR-T manufacturing explained.

The Bear Case

CAR-T is not a free lunch. Three risks could slow the sector:

1. Cytokine release syndrome (CRS) and neurotoxicity. The most common serious adverse events with CAR-T are CRS (occurs in 50% to 80% of patients, severe in 5% to 10%) and ICANS (immune effector cell-associated neurotoxicity syndrome, occurs in 20% to 40%). These are manageable with tocilizumab and steroids, but they add cost, lengthen hospital stays, and limit outpatient administration. Until CAR-T can be given safely in an outpatient setting, the cost per patient includes a 2-3 week hospitalization.

2. Payers pushing back on price. The current CAR-T price is $375,000 to $475,000 per dose. With hospitalization and ancillary costs, the total per-patient cost is $500,000 to $1 million. CMS covers CAR-T under its inpatient DRG, but the reimbursement does not always cover the full cost. Commercial payers are increasingly requiring prior authorization. If iberdomide and other CELMoDs extend the time to CAR-T, some patients may never need CAR-T, which is good for patients but reduces the CAR-T market size.

3. Bispecific antibodies cannibalizing CAR-T. Bispecifics like teclistamide (Tecvayli) and talquetamab (Talvey) target the same BCMA pathway as CAR-T but are off-the-shelf drugs administered subcutaneously. They are less durable than CAR-T (median PFS 9-15 months vs. 18+ months for the best CAR-Ts), but they are cheaper and easier to administer. The trade-off is durability for convenience. For the full analysis of this trade-off, see our bispecifics guide.

The Investor Framework

The CAR-T market is growing at 11.9% CAGR, but the stocks that capture that growth depend on which segment you are betting on:

1. Bet on incumbents (BMY, GILD) if you want lower volatility. These companies move 5% to 10% on CAR-T catalysts. The iberdomide approval is a tailwind for BMY’s myeloma franchise, which includes both the CELMoD and Abecma CAR-T. GILD’s anito-cel PDUFA is the next binary event.

2. Bet on pure-plays (AUTL, ALLO, IPSC) if you want higher upside. These stocks move 50% to 100% on trial readouts. The risk is that one failed trial cuts the stock in half. Position size accordingly: 1% to 2% of a biotech portfolio per name.

3. Bet on manufacturing innovation if you want to avoid binary clinical risk. In vivo CAR-T (JNJ’s platform) and point-of-care manufacturing are the long-term plays. If either works at scale, the cost per CAR-T dose drops from $500,000 to under $200,000, and the addressable market expands 3x to 5x because outpatient administration becomes possible.

The sector is surging because the pieces are coming together: better bridging therapy (CELMoDs), better CAR-T designs (anito-cel), and better manufacturing (in vivo, allogeneic). The market is growing, the data is improving, and the cost curve is bending down. That is why CAR-T stocks are moving in 2026.